The Rutgers Cancer Institute of New Jersey announced it has begun a clinical trial that will examine whether an anti-malaria drug doctors are administering as an off-label use to treat the coronavirus is more effective when taken with an antibiotic. Clinical trials take year to complete. But Rutgers, a nationally recognized comprehensive cancer center, has the in-house expertise to move faster, said Rutgers Cancer Institute Director Steven K. Libutti, who is overseeing the trial. To read the full article.
Recent Posts
- Join NJ ACTS for a Seminar on Clinical Research Record Retention on 3/2 at 12
- CTSA Translational Impact Summit on March 2&3 (Virtual) – Register Now!
- Join NJ ACTS for Boosted: The Impact of Science, Society, and Policy on Public Health on 2/27 at 12
- NJACTS Community Engagement Core COVID-19 Resources
- Join NJ ACTS on 2/12 at 4pm for the Pilots Program 2026 Webinar
Categories
- Community (2,439)
- Covid (997)
- CTO Events (6)
- News (3,091)
- Pilots (21)